

Nr. crt.	Cod protocol	Numar EudraCT	Medicament de investigatie clinica testat	Medicament de investigatie clinica comparator	Placebo	Aria terapeutică	Sponsor	International / national	Denumirea studiului (s-a pastrat denumirea originala - in limba engleza)	Faza	Nr. estimat de pacienti pentru Romania	Data autorizarii studiului clinic de catre ANMDM	Data opiniei CNBMDM	Data inceperii studiului	Inchidere studiu la nivel global/ Romania
1	CA017-078	2017-004692-31	IDO-1 inhibitor BMS-986205 Nivolumab BMS-936558 Gemcitabine Cisplatin			Afectiuni oncologice	Bristol-Myers Squibb International Corporation, Belgia	multicentric	A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer	III	30	10/31/2019	1/28/2019		
2	CL3-95005-006	2017-004059-22	S95005			Afectiuni oncologice	Institut de Recherches Internationales Servier, Franța	multicentric	An open-label, randomised, phase III Study comparing trifluridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in first-line treatment of patients with metastatic colorectal cancer who are not candidates for intensive therapy (SOLSTICE study)	III	63	10/31/2019	10/14/2019		
3	D081RC00001	2017-004632-11	Durvalumab MEDI4736			Afectiuni oncologice	AstraZeneca AB, Suedia	multicentric	A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O)	III	47	10/31/2019	6/18/2019		
4	BGB-290-303	2017-003493-13	BGB-290			Afectiuni oncologice	BeiGene Ltd., SUA	multicentric	A Phase 3, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy	III	27	10/31/2019			
5	Brigatinib-3001	2018-001957-29	Brigatinib AP26113			Afectiuni oncologice	ARIAD Pharmaceuticals, Inc., SUA	multicentric	A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive on-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKOR®)	III	10	10/31/2019	7/18/2019		
6	CTQJ230A12001	2018-003786-34	fara medicament			Boli cardiovasculare	Novartis Pharma AG, Elveția	multicentric	Multi-center cross-sectional epidemiological study to characterize the prevalence and distribution of lipoprotein(a) levels among patients with established cardiovascular disease	IV	800	10/31/2019			
7	8951-CL-0302	2018-000519-26	Zolbetuximab IMAB362			Afectiuni oncologice	Astellas Pharma Global Development, Inc. (APGD), SUA	multicentric	A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma	III	22	10/31/2019	1/31/2019		
8	CT-P16 3.1	2018-002147-28	CT-P16			Afectiuni oncologice	CELLTRION, Inc., Korea	multicentric	A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non Squamous Non Small Cell Lung Cancer	III	20	10/31/2019	1/16/2019		
9	CINC280D2201	2018-001420-19	INC280			Afectiuni oncologice	Novartis Pharma AG, Elveția	unicentric	A phase II, multicenter, randomized, two-arm study of capmatinib (INC280, an oral MET inhibitor) and spartalizumab (PDR001, a PD-1 inhibitor) combination therapy versus docetaxel in pretreated adult patients with EGFR wild-type, ALK rearrangement negative locally advanced/metastatic non-small cell lung cancer	II	4	10/31/2019	4/9/2019		
10	OBS14099/ELISAFE studiu non-interventional		Cerdelga/Eliglustat			Boala Gaucher	Sanofi Genzyme, SUA	unicentric	A prospective multicenter observational post authorization safety sub-registry to characterize the long-term safety profile of commercial use of eliglustat (Cerdelga®) in adult patients with Gaucher disease			10/31/2019			
11	D169CC00001	2018-000802-46	Dapagliflozin			Boli cardiovasculare	AstraZeneca AB, Suedia	multicentric	An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction	III	200	10/31/2019	2/11/2019		

12	D5680C00002	2018-002523-42	MEDI7352			Neuropatie diabetică	AstraZeneca AB, Suedia	multicentric	A randomised, double-blind, placebo-controlled, dose-response study of the efficacy and safety of MEDI7352 in subjects with painful diabetic neuropathy	II	128	10/31/2019	1/10/2019		
13	I8F-MC-GPGM	2018-002618-11	LY3298176			Diabet zaharat de tip 2 și risc cardiovascular crescut	Eli Lilly and Company, SUA	multicentric	Efficacy and Safety of LY3298176 Once Weekly versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)	III	115	10/31/2019	4/15/2019		
14	BGB-A317-305	2018-000312-24	Tislelizumab BGB-A317			Afecțiuni oncologice	BeiGene Ltd., SUA	multicentric	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) plus Platinum and Fluoropyrimidine Versus Placebo plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	III	23	10/31/2019	5/30/2019		
15	WHITE studiu non-interventional		fara medicament			Tromboembolism	Fondazione Arianna Anticoagulazione, Bologna (Italy)	multicentric	WHITE Study: Which decision after a first venous ThromboEmbolism? [Multicenter, multinational, investigators-initiated, observational, prospective study to evaluate the decisions taken by clinicians at the end of the maintenance treatment of subjects with a first-ever event of deep vein thrombosis of the lower limbs and/or pulmonary embolism, the relevant reasons, and the attending long-term outcomes]			10/31/2019			